The US government has agreed to buy 1.5 million more doses of Novavax COVID-19 vaccine, the company said. It also informed that the modified agreement includes funds for the development of an updated vaccine by fall this year.
The protein-based vaccine was expected to convince those sceptical of the new mRNA-based vaccines against the virus from rivals such as Pfizer and Moderna.
The deal comes even as the US plans to end its COVID-19 emergency declarations on May 11. Novavax did not provide the financial details of the contract.
The US Food and Drug Administration is also in the process of simplifying its COVID-19 vaccine policy as it considers whether to recommend that Americans get an annual booster shot for the virus.